Tesamorelin
FDA-approved growth hormone releasing factor — subcutaneous injection
Built for those who prefer clarity over complexity. The only FDA-approved protocol specifically designed for visceral fat reduction, available through a streamlined digital intake and physician review process.
About this solution
Tesamorelin is an FDA-approved growth hormone releasing factor available through a streamlined digital intake and physician-reviewed approval process. It is the only compound in its class with FDA approval, supported by multiple randomized controlled trials demonstrating reduction in visceral adipose tissue.
What’s included
- Simple digital intake.
- Physician review where required.
- Discreet fulfillment and delivery.
- IGF-1 monitoring recommended at 8–12 weeks.
All solutions require evaluation and approval by a licensed Nuvora provider. Not all patients will qualify. Results vary. This page is for informational purposes only and does not constitute medical advice.
Pricing
Pricing confirmed at physician approval.
Recommended Lab Support
Baseline labs help personalize your protocol and support safer prescribing.
Tesamorelin Standard Panel
The clinically recommended baseline for patients starting Tesamorelin.
- —CMP
- —CBC
- —IGF-1
- —Fasting Glucose
- —Lipid Panel
The clinically recommended baseline for patients starting Tesamorelin. IGF-1 monitoring is essential for safe and effective use.
+$129
Tesamorelin Comprehensive Panel
Full metabolic and hormone panel for maximum clinical visibility before starting Tesamorelin.
- —CMP
- —CBC
- —IGF-1
- —Fasting Glucose
- —Lipid Panel
- —HbA1c
- —TSH
- —Free T4
- —Morning Cortisol
- —DHEA-S
Full metabolic and hormone panel for patients seeking maximum clinical visibility before starting Tesamorelin.
+$219